Txl Active Wart Corn Remover Bandage

Description

No relevant information is available for SPL code 34089-3.

Uses and Indications

This drug is indicated for the removal of common warts, plantar warts, corns, and small calluses.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed with soap and warm water, followed by thorough rinsing and complete drying. The appropriate size pad, either large or small, must be selected to fit the wart, corn, or small callus. The medicated center should be applied directly over the lesion, ensuring that healthy skin is not covered.

To secure the pad in place, the provided PU adhesive bandage should be used, ensuring it remains firmly attached. The pad should be left in place for a duration of 24 hours. After this period, the pad must be removed, and the affected area should be cleaned again.

This application process may be repeated daily as needed until the wart, corn, or callus is fully removed. It is important to note that the treatment should not exceed 12 weeks unless directed by a healthcare professional.

Contraindications

Use is contraindicated on open wounds, irritated or infected skin, skin tags, moles, facial warts, genital warts, Molluscum, milia (white bumps), or mucous membranes.

Additionally, contact with eyes or healthy skin should be avoided. In the event of accidental contact, rinse thoroughly with water.

Warnings and Precautions

For external use only. It is imperative to avoid contact with the eyes or healthy skin. In the event of accidental contact, the affected area should be rinsed thoroughly with water to mitigate any potential adverse effects.

Healthcare professionals should advise patients to seek emergency medical assistance or contact a Poison Control Center immediately if the product is ingested.

Patients are also instructed to discontinue use and consult their healthcare provider if any of the following occur: redness, irritation, swelling, or pain that persists or worsens, or if the wart, corn, or callus does not show improvement within the expected treatment period of up to 12 weeks. Regular monitoring of these symptoms is essential to ensure patient safety and treatment efficacy.

Side Effects

Patients using this product may experience adverse reactions, which can be categorized based on seriousness and frequency.

For external use only, the product may lead to localized reactions such as redness, irritation, swelling, or pain. These symptoms should be monitored closely. If any of these reactions persist or worsen, it is advised that patients discontinue use and consult a healthcare professional.

Additionally, if the wart, corn, or callus does not show improvement within the expected treatment period of up to 12 weeks, patients should seek medical advice. This recommendation applies to both the persistence of localized reactions and the lack of improvement in the treated condition.

It is essential for patients to be aware of these potential adverse reactions to ensure appropriate management and to seek medical attention when necessary.

Drug Interactions

There are no specific drug interactions identified for this medication. Additionally, no laboratory test interactions have been reported. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Txl Active Wart Corn Remover Bandage (wart corn remover pads). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients should be aware that no specific information regarding the use of this product during pregnancy is provided in the prescribing information. There are no statements indicating whether the product is contraindicated in pregnancy or any associated risks to the fetus. Additionally, no dosage modifications or special precautions regarding the use of this product during pregnancy are mentioned. Healthcare professionals should consider the lack of data when advising women of childbearing potential and weigh the potential benefits against any unknown risks.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or lactation considerations. Healthcare professionals should exercise caution and consider the potential risks and benefits when prescribing this medication to lactating mothers. Further research may be necessary to fully understand the implications for breastfed infants.

Renal Impairment

There is no specific information regarding renal impairment, dosage adjustments, special monitoring, or safety considerations for patients with reduced kidney function provided in the insert text. Healthcare professionals should exercise caution when prescribing to patients with renal impairment, as the absence of detailed guidance necessitates careful clinical judgment and monitoring.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include monitoring vital signs, providing symptomatic treatment, and ensuring the patient's safety.

If available, consultation with a poison control center or a medical toxicologist is recommended to guide the management of the overdose effectively.

Documentation of the incident, including the substance involved, the amount taken, and the time of ingestion, is crucial for appropriate treatment and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the medication is swallowed. It is crucial for patients to understand the importance of prompt action in such situations.

Additionally, healthcare providers should emphasize the need to avoid contact with the eyes or healthy skin. In the event of accidental contact, patients should be instructed to rinse the affected area thoroughly with water to minimize any potential adverse effects.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product within a temperature range of 59° to 86°F (15°C to 30°C) to maintain its efficacy and integrity. Proper storage conditions must be adhered to, ensuring that the product is kept in a suitable container that protects it from environmental factors. Special handling requirements should be observed to prevent any compromise to the product's quality.

Additional Clinical Information

The route of administration for the product is topical. There is no additional information available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Txl Active Wart Corn Remover Bandage, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)